Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
IDIX's Cash to Debt is ranked higher than
93% of the 896 Companies
in the Global Biotechnology industry.

( Industry Median: 171.30 vs. IDIX: No Debt )
IDIX' s 10-Year Cash to Debt Range
Min: 3.36   Max: 21742.5
Current: No Debt

3.36
21742.5
Equity to Asset 0.75
IDIX's Equity to Asset is ranked higher than
79% of the 759 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. IDIX: 0.75 )
IDIX' s 10-Year Equity to Asset Range
Min: -13.2   Max: 0.87
Current: 0.75

-13.2
0.87
Interest Coverage No Debt
IDIX's Interest Coverage is ranked higher than
73% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. IDIX: No Debt )
IDIX' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 1
Z-Score: 3.95
M-Score: 117.60
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -26379.53
IDIX's Operating margin (%) is ranked lower than
53% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -66.98 vs. IDIX: -26379.53 )
IDIX' s 10-Year Operating margin (%) Range
Min: -26379.53   Max: -8.59
Current: -26379.53

-26379.53
-8.59
Net-margin (%) -26073.99
IDIX's Net-margin (%) is ranked lower than
53% of the 781 Companies
in the Global Biotechnology industry.

( Industry Median: -56.37 vs. IDIX: -26073.99 )
IDIX' s 10-Year Net-margin (%) Range
Min: -26073.99   Max: -6.55
Current: -26073.99

-26073.99
-6.55
ROE (%) -115.37
IDIX's ROE (%) is ranked higher than
53% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: -21.52 vs. IDIX: -115.37 )
IDIX' s 10-Year ROE (%) Range
Min: -954.79   Max: -5.73
Current: -115.37

-954.79
-5.73
ROA (%) -86.72
IDIX's ROA (%) is ranked higher than
52% of the 890 Companies
in the Global Biotechnology industry.

( Industry Median: -18.90 vs. IDIX: -86.72 )
IDIX' s 10-Year ROA (%) Range
Min: -313.72   Max: -3.34
Current: -86.72

-313.72
-3.34
ROC (Joel Greenblatt) (%) -4447.16
IDIX's ROC (Joel Greenblatt) (%) is ranked higher than
54% of the 868 Companies
in the Global Biotechnology industry.

( Industry Median: -189.80 vs. IDIX: -4447.16 )
IDIX' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -4447.16   Max: -120.4
Current: -4447.16

-4447.16
-120.4
Revenue Growth (%) -100.00
IDIX's Revenue Growth (%) is ranked higher than
51% of the 589 Companies
in the Global Biotechnology industry.

( Industry Median: -0.40 vs. IDIX: -100.00 )
IDIX' s 10-Year Revenue Growth (%) Range
Min: -100   Max: 235.2
Current: -100

-100
235.2
EBITDA Growth (%) 0.70
IDIX's EBITDA Growth (%) is ranked higher than
82% of the 597 Companies
in the Global Biotechnology industry.

( Industry Median: -10.60 vs. IDIX: 0.70 )
IDIX' s 10-Year EBITDA Growth (%) Range
Min: -69.4   Max: 105.7
Current: 0.7

-69.4
105.7
EPS Growth (%) 1.50
IDIX's EPS Growth (%) is ranked higher than
83% of the 617 Companies
in the Global Biotechnology industry.

( Industry Median: -12.60 vs. IDIX: 1.50 )
IDIX' s 10-Year EPS Growth (%) Range
Min: -77.4   Max: 114
Current: 1.5

-77.4
114
» IDIX's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2013

IDIX Guru Trades in Q1 2013

Jeremy Grantham 17,500 sh (New)
Jim Simons 575,866 sh (New)
Seth Klarman 26,042,000 sh (+25.78%)
John Burbank Sold Out
Steven Cohen Sold Out
» More
Q2 2013

IDIX Guru Trades in Q2 2013

Chuck Royce 736,000 sh (New)
Jeremy Grantham 29,600 sh (+69.14%)
Seth Klarman 26,767,000 sh (+2.78%)
Jim Simons 16,466 sh (-97.14%)
» More
Q3 2013

IDIX Guru Trades in Q3 2013

Seth Klarman 29,665,693 sh (+10.83%)
Chuck Royce 736,000 sh (unchged)
Jim Simons Sold Out
Jeremy Grantham 21,600 sh (-27.03%)
» More
Q4 2013

IDIX Guru Trades in Q4 2013

Steven Cohen 13,900 sh (New)
Jeremy Grantham 56,100 sh (+159.72%)
Seth Klarman 36,910,868 sh (+24.42%)
Chuck Royce 665,980 sh (-9.51%)
» More
» Details

Insider Trades

Latest Guru Trades with IDIX

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Seth Klarman 2013-12-31 Add 24.42%1.24%$3.29 - $6.93 $ 5.5320%36910868
Seth Klarman 2013-09-30 Add 10.83%0.43%$3.22 - $5.75 $ 5.5326%29665693
Seth Klarman 2013-03-31 Add 25.78%0.61%$3.54 - $5.36 $ 5.5320%26042000
John Burbank 2013-03-31 Sold Out 0.19%$3.54 - $5.36 $ 5.5320%0
Seth Klarman 2012-12-31 Add 72.54%1.35%$3.52 - $5.3 $ 5.5323%20704700
Jean-Marie Eveillard 2012-12-31 Sold Out 0.0025%$3.52 - $5.3 $ 5.5323%0
Seth Klarman 2012-09-30 Add 20%0.28%$4.39 - $11.06 $ 5.53-30%12000000
Jean-Marie Eveillard 2012-09-30 New Buy$4.39 - $11.06 $ 5.53-30%150000
Seth Klarman 2012-06-30 Add 21.23%0.47%$7.24 - $10.71 $ 5.53-38%10000000
John Burbank 2012-06-30 Add 150%0.26%$7.24 - $10.71 $ 5.53-38%1250000
Seth Klarman 2012-03-31 Add 45.61%0.85%$7.01 - $14.89 $ 5.53-50%8249000
John Burbank 2012-03-31 New Buy0.17%$7.01 - $14.89 $ 5.53-50%500000
George Soros 2012-03-31 Sold Out 0.08%$7.01 - $14.89 $ 5.53-50%0
Seth Klarman 2011-12-31 Add 126.6%0.73%$4.55 - $8.22 $ 5.53-15%5665000
George Soros 2011-12-31 Add 1382.72%0.08%$4.55 - $8.22 $ 5.53-15%255028
Seth Klarman 2011-09-30 Add 99.09%0.21%$4.15 - $6.96 $ 5.53-3%2500000
George Soros 2011-09-30 New Buy$4.15 - $6.96 $ 5.53-3%17200
Seth Klarman 2011-06-30 New Buy0.26%$2.9 - $5.3 $ 5.5319%1255700
Premium More recent guru trades are included for Premium Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Idenix Pharmaceuticals Inc

Seth Klarman Amasses a Third of Drug Company, George Soros Adds Mercury Systems
Two well-known gurus, George Soros and Seth Klarman, bought additional shares of companies of which they own more than 5%, according to GuruFocus Real Time Picks. Klarman, leader of the Baupost Group, added shares to his position in Idenix Pharmaceuticals (IDIX), and Soros grew his position in Mercury Systems (MRCY). Read more...

Ratios

vs
industry
vs
history
P/B 7.60
IDIX's P/B is ranked lower than
53% of the 787 Companies
in the Global Biotechnology industry.

( Industry Median: 4.51 vs. IDIX: 7.60 )
IDIX' s 10-Year P/B Range
Min: 1.28   Max: 74.22
Current: 7.6

1.28
74.22
P/S 1666.67
IDIX's P/S is ranked lower than
92% of the 785 Companies
in the Global Biotechnology industry.

( Industry Median: 10.38 vs. IDIX: 1666.67 )
IDIX' s 10-Year P/S Range
Min: 0   Max: 1783.8
Current: 1666.67

0
1783.8
EV-to-EBIT 0.60
IDIX's EV-to-EBIT is ranked higher than
92% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 20.00 vs. IDIX: 0.60 )
IDIX' s 10-Year EV-to-EBIT Range
Min: 63.5   Max: 96.8
Current: 0.6

63.5
96.8

Valuation & Return

vs
industry
vs
history
Price/Net Cash 9.10
IDIX's Price/Net Cash is ranked higher than
56% of the 476 Companies
in the Global Biotechnology industry.

( Industry Median: 9.10 vs. IDIX: 9.10 )
IDIX' s 10-Year Price/Net Cash Range
Min: 3.26   Max: 343
Current: 9.1

3.26
343
Price/Net Current Asset Value 9.00
IDIX's Price/Net Current Asset Value is ranked higher than
57% of the 520 Companies
in the Global Biotechnology industry.

( Industry Median: 9.30 vs. IDIX: 9.00 )
IDIX' s 10-Year Price/Net Current Asset Value Range
Min: 3.26   Max: 55.32
Current: 9

3.26
55.32
Price/Tangible Book 7.50
IDIX's Price/Tangible Book is ranked lower than
51% of the 727 Companies
in the Global Biotechnology industry.

( Industry Median: 6.00 vs. IDIX: 7.50 )
IDIX' s 10-Year Price/Tangible Book Range
Min: 2.76   Max: 18.61
Current: 7.5

2.76
18.61
Price/Median PS Value 1.50
IDIX's Price/Median PS Value is ranked higher than
86% of the 717 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. IDIX: 1.50 )
IDIX' s 10-Year Price/Median PS Value Range
Min: 0.15   Max: 6.26
Current: 1.5

0.15
6.26
Forward Rate of Return (Yacktman) -23.96
IDIX's Forward Rate of Return (Yacktman) is ranked higher than
68% of the 669 Companies
in the Global Biotechnology industry.

( Industry Median: -9.87 vs. IDIX: -23.96 )
IDIX' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -50.3   Max: -32
Current: -23.96

-50.3
-32

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:NO9.Germany
Idenix Pharmaceuticals, Inc. is a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases with operations in the United States and Europe. The Company's main research and development focus is on the treatment of hepatitis C virus, or HCV. HCV is a cause of liver disease. The Company is currently developing nucleoside/nucleotide polymerase inhibitors and NS5A inhibitors to inhibit HCV replication. The Company has developed a non-nucleoside reverse transcriptase inhibitor, or NNRTI, drug candidate, IDX899, for the treatment of human immunodeficiency virus type-1, or HIV, and acquired immune deficiency syndrome, or AIDS, for use in combination therapy. In 2008, it successfully completed a proof-of-concept clinical trial of IDX899 in treatment-naïve HIV-infected patients. In February 2009, it licensed its NNRTI compounds to GlaxoSmithKline. In collaboration with Novartis, it developed telbivudine (Tyzeka/Sebivo) through commercialization for the treatment of patients with HBV. In October 2006, the FDA approved Tyzeka in the United States and Sebivo was approved in 2007 in more than 50 countries outside the United States, including major Asian countries and several countries included in the European Union. Companies the compete with in the HCV market include Abbott Laboratories, Boehringer Ingelheim International GmbH, F. Hoffman-LaRoche & Co., Johnson & Johnson, Merck & Co., Inc., Bristol-Myers Squibb Company, Novartis, Gilead Sciences, Inc., Vertex Pharmaceuticals, Inc., Achillion Pharmaceuticals, Inc., Enanta Pharmaceuticals, Inc., and Presidio Pharmaceuticals, Inc. The Company is subject to federal, state and local laws and regulations governing the use, manufacture, storage, handling and disposing of hazardous materials and waste products, including certain regulations promulgated by the U.S. Environmental Protection Agency, or EPA.

Personalized Checklist








Within your circle of competence?
Macro economic environment favorable?
High quality business?
Enough margin of safety with stocks?
Gurus are buying?
Insiders are buying?
Management capable and shareholder friendly?
Catalyst for stock price to appreciate?
Your level of confidence with the research?

Add Notes, Comments or Ask Questions

User Comments

No comment yet

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK
Hide